Anti-Cocaine Vaccine in the Works
US researchers say they have developed a vaccine that may someday help cocaine addicts kick their habits. The vaccine combines a segment of the common cold virus with a molecule similar to cocaine, according to a study published in the online edition of Molecular Therapy.
US researchers say they have developed a vaccine that may someday help cocaine addicts kick their habits. The vaccine combines a segment of the common cold virus with a molecule similar to cocaine, according to a study published in the online edition of Molecular Therapy.
The vaccine is made of proteins from a harmless cold virus and a molecule that mimics cocaine. It works by turning the body's immune system against cocaine, preventing the drug from reaching the brain, said Ronald Crystal of the Department of Genetic Medicine at Weill Cornell Medical College in New York in the study. Crystal led a team of researchers that vaccinated mice and then injected them with cocaine.
The study, which was funded by the US National Institute on Drug Abuse, triggered an immune response in mice which prevented them from getting high on cocaine for as long as 13 weeks after they were vaccinated.
There is currently no FDA approved vaccine for any drug addiction. The drug will have to undergo extensive testing in humans to ensure its safety and effectiveness before it could receive an approval from the FDA.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
